{"id":357912,"date":"2023-05-08T16:58:05","date_gmt":"2023-05-08T14:58:05","guid":{"rendered":"https:\/\/medizinonline.com\/therapy-if-intensive-chemotherapy-is-not-possible\/"},"modified":"2023-05-15T09:53:36","modified_gmt":"2023-05-15T07:53:36","slug":"therapy-if-intensive-chemotherapy-is-not-possible","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/therapy-if-intensive-chemotherapy-is-not-possible\/","title":{"rendered":"Therapy &#8211; if intensive chemotherapy is not possible"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>AML predominantly affects older individuals, who are often not suitable for intensive chemotherapy due to their age and pre-existing conditions. Younger patients may also be ineligible for intensive chemotherapy due to comorbidities or unfavorable genetic characteristics<sup>.1<\/sup> Treatment with Venclyxto\u00ae + Aza was shown to be effective in this group of patients with newly diagnosed AML in the VIALE- A trial (NCT02993523)<sup>.1<\/sup> In the webcast, PD. Boris Schleiffenbaum, MD, presented the current study data and a patient case.  <\/strong><\/p>\n\n<!--more-->\n\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" data-src=\"https:\/\/medizinonline.com\/wp-content\/uploads\/2023\/04\/4159-pd-dr-med-boris-schleiffenbaum-1.webp\" alt=\"\" class=\"wp-image-357079 lazyload\" width=\"219\" height=\"219\" data-srcset=\"https:\/\/medizinonline.com\/wp-content\/uploads\/2023\/04\/4159-pd-dr-med-boris-schleiffenbaum-1.webp 400w, https:\/\/medizinonline.com\/wp-content\/uploads\/2023\/04\/4159-pd-dr-med-boris-schleiffenbaum-1-80x80.webp 80w, https:\/\/medizinonline.com\/wp-content\/uploads\/2023\/04\/4159-pd-dr-med-boris-schleiffenbaum-1-120x120.webp 120w, https:\/\/medizinonline.com\/wp-content\/uploads\/2023\/04\/4159-pd-dr-med-boris-schleiffenbaum-1-90x90.webp 90w, https:\/\/medizinonline.com\/wp-content\/uploads\/2023\/04\/4159-pd-dr-med-boris-schleiffenbaum-1-320x320.webp 320w\" data-sizes=\"(max-width: 219px) 100vw, 219px\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" style=\"--smush-placeholder-width: 219px; --smush-placeholder-aspect-ratio: 219\/219;\" \/><\/figure>\n\n<div class=\"wp-block-group is-vertical is-layout-flex wp-container-core-group-is-layout-2c90304e wp-block-group-is-layout-flex\">\n<p class=\"wp-block-paragraph\"><strong>PD Dr. med. Boris Schleiffenbaum<\/strong><br\/>Hematology and General Internal Medicine<br\/>Hirslanden Group<\/p>\n<\/div>\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n<figure class=\"wp-block-embed is-type-video is-provider-vimeo wp-block-embed-vimeo wp-embed-aspect-16-9 wp-has-aspect-ratio\"><div class=\"wp-block-embed__wrapper\">\n<iframe title=\"Webcaste_Schleiffenbaum_JBe_1.2\" data-src=\"https:\/\/player.vimeo.com\/video\/822050035?h=b0d60194ea&amp;dnt=1&amp;app_id=122963\" width=\"1160\" height=\"653\" frameborder=\"0\" allow=\"autoplay; fullscreen; picture-in-picture\" allowfullscreen src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" class=\"lazyload\" data-load-mode=\"1\"><\/iframe>\n<\/div><\/figure>\n\n<p class=\"wp-block-paragraph\">Dr. sc. nat. Katja Becker<\/p>\n\n<p class=\"wp-block-paragraph\">This article was produced with the financial support of AbbVie AG, Alte Steinhauserstrasse 14, Cham.<\/p>\n\n<p class=\"wp-block-paragraph\">CH-VNCAML-230008 04\/2023<\/p>\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/medizinonline.com\/en\/brief-subject-information\/\">The brief technical information of <\/a><a href=\"https:\/\/medizinonline.com\/en\/brief-subject-information\/\" target=\"_blank\" rel=\"noreferrer noopener\">Venetoclax<\/a><a href=\"https:\/\/medizinonline.com\/en\/brief-subject-information\/\">\u00ae<\/a> <\/p>\n\n<p class=\"wp-block-paragraph\"><strong>Literature<\/strong><\/p>\n\n<p class=\"wp-block-paragraph\">1. DiNardo CD et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia<em>.<\/em> N Engl J Med, 2020. 383(7): p. 617-629.<\/p>\n\n<p class=\"wp-block-paragraph\"> The references can be requested by professionals at medinfo.ch@abbvie.com.<\/p>\n\n<p class=\"wp-block-paragraph\">Post online since 08.05.2023<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AML predominantly affects older individuals, who are often not suitable for intensive chemotherapy due to their age and pre-existing conditions. Younger patients may also be ineligible for intensive chemotherapy due&hellip;<\/p>\n","protected":false},"author":17,"featured_media":357916,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Acute myeloid leukemia","footnotes":""},"category":[11297,11353,11370,11323,11548],"tags":[],"powerkit_post_featured":[],"class_list":["post-357912","post","type-post","status-publish","format-standard","has-post-thumbnail","category-general-internal-medicine","category-hematology","category-oncology","category-partner-content-en","category-rx-en","pmpro-has-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-07-13 14:49:56","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":357911,"slug":"therapie-si-la-chimiotherapie-intensive-nest-pas-possible","post_title":"Th\u00e9rapie - si la chimioth\u00e9rapie intensive n'est pas possible","href":"https:\/\/medizinonline.com\/fr\/therapie-si-la-chimiotherapie-intensive-nest-pas-possible\/"},"it_IT":{"locale":"it_IT","id":357914,"slug":"terapia-se-la-chemioterapia-intensiva-non-e-possibile","post_title":"Terapia - se la chemioterapia intensiva non \u00e8 possibile","href":"https:\/\/medizinonline.com\/it\/terapia-se-la-chemioterapia-intensiva-non-e-possibile\/"},"pt_PT":{"locale":"pt_PT","id":357913,"slug":"terapia-se-a-quimioterapia-intensiva-nao-for-possivel","post_title":"Terapia - se a quimioterapia intensiva n\u00e3o for poss\u00edvel","href":"https:\/\/medizinonline.com\/pt-pt\/terapia-se-a-quimioterapia-intensiva-nao-for-possivel\/"},"es_ES":{"locale":"es_ES","id":357915,"slug":"terapia-si-la-quimioterapia-intensiva-no-es-posible","post_title":"Terapia - si la quimioterapia intensiva no es posible","href":"https:\/\/medizinonline.com\/es\/terapia-si-la-quimioterapia-intensiva-no-es-posible\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/357912","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/17"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=357912"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/357912\/revisions"}],"predecessor-version":[{"id":357918,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/357912\/revisions\/357918"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/357916"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=357912"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=357912"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=357912"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=357912"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}